Study Background and Disease Burden
Acute ischemic stroke (AIS) is a leading cause of long-term disability and mortality worldwide, imposing substantial clinical and socioeconomic burdens. Despite advances in reperfusion strategies such as thrombolysis and mechanical thrombectomy, many patients experience significant neurological deficits due to ischemic injury and subsequent reperfusion-related oxidative stress and inflammation. Edaravone dexborneol is a novel multitarget cytoprotective agent combining the free radical scavenging properties of edaravone and the anti-inflammatory effects of dexborneol, aiming to mitigate ischemic brain injury via multiple pathways. Previous clinical trials have suggested potential efficacy in improving neurological outcomes post-stroke; however, its real-world clinical effectiveness and safety profile remain to be fully established, particularly across diverse patient populations and routine practice settings. This gap highlights the need for contemporary observational studies to inform translation of trial evidence into clinical practice.
